Cargando…

P1728: THE FUTURE OF MYELODYSPLASTIC SYNDROME – PATIENT PRIORITIES AND OUTCOMES THAT MATTER

Detalles Bibliográficos
Autores principales:	Poynton, M., Hamilton Gilmour, C., Dale-Harris, I., Clarke, E., Stanworth, S., Murphy, M., Roy, N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431220/ http://dx.doi.org/10.1097/01.HS9.0000849768.38506.cd

Ejemplares similares

John Freind, 1675—1728
Publicado: (1972)

John Hunter 1728–1793
por: Brock, C. Helen
Publicado: (1983)

P1661: THROMBOPATHY IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND AUTOIMMUNE DISEASE
por: Garcia Perez, E., et al.
Publicado: (2022)

Albrecht Von Hallers Briefe an Johannes Gesner (1728-1777)
por: Riesman, David
Publicado: (1925)

P741: PATIENTS’ PERSPECTIVES ON ORAL DECITABINE AND CEDAZURIDINE FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES
por: Zeidan, Amer M., et al.
Publicado: (2023)

P743: CLINICAL OUTCOMES OF PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SPLICEOSOME MUTATIONS
por: Urrutia, Samuel, et al.
Publicado: (2023)

P728: EVALUATION OF IPSS-M IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SPLICEOSOME MUTATIONS
por: Urrutia, Samuel, et al.
Publicado: (2023)

P724: UPDATED SUBSTUDY RESULTS FOR IVOSIDENIB IN IDH1-MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME
por: Dinardo, Courtney, et al.
Publicado: (2023)

P748: IPSS-M PERFORMANCE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AT THE TIME OF HYPOMETHYLATING AGENT FAILURE
por: Urrutia, Samuel, et al.
Publicado: (2023)

P744: A REAL-WORLD STUDY OF MULTIPLE-CYCLE HYPOMETHYLATING AGENTS MONOTHERAPY IN MYELODYSPLASTIC SYNDROMES
por: Liu, Xiaozhen, et al.
Publicado: (2023)

P714: DISSECTING THE CLINICAL HETEROGENEITY OF ISOLATED TRISOMY 8 MYELODYSPLASTIC SYNDROMES THROUGH MUTATIONAL PROFILE
por: María Toribio Castelló, Sofía, et al.
Publicado: (2023)

Protease with collagenolytic activity produced by Bacillus sp. DPUA 1728 from Amazonian soil
por: Lima, Lorena A., et al.
Publicado: (2015)

P1728 Multiplexed molecular testing for the detection of human respiratory viruses using the TM Bioscience ID-Tag RVP assay
por: Manji, R., et al.
Publicado: (2007)

P704: ABERRANT IMMUNE MICROENVIRONMENT IN BONE MARROW OF MYELODYSPLASTIC SYNDROME PATIENTS DRIVES A SUPPRESSIVE PHENOTYPE
por: Rai, Richa, et al.
Publicado: (2023)

P492: SAFETY AND EFFICACY OF LP-108 AS MONOTHERAPY AND COMBINED WITH AZACITIDINE IN PATIENTS WITH RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA, OR ACUTE MYELOID LEUKEMIA
por: Koenig, Kristin, et al.
Publicado: (2023)

Effect of a Soluble Epoxide Hydrolase Inhibitor, UC1728, on LPS-Induced Uveitis in the Rabbit
por: McLellan, Gillian J., et al.
Publicado: (2016)

P1647: CONTRIBUTION OF NEXT GENERATION FLOW (NGF) CYTOMETRY IN PRIMARY IMMUNE THROMBOCYTOPENIA (ITP): UTILITY FOR THE DIFFERENTIAL DIAGNOSIS WITH MYELODYSPLASTIC SYNDROMES
por: Gonzalez-Lopez, T. J., et al.
Publicado: (2022)

P711: THE PREVALENCE OF FOXP3-E2 ISOFORM IN REGULATORY T CELLS CORRELATES WITH THE DEGREE OF DYSPLASIA IN MYELODYSPLASTIC SYNDROMES
por: Leone, Stefania, et al.
Publicado: (2023)

P739: INCREASED FOXO1 EXPRESSION IS ASSOCIATED WITH BETTER PROGNOSIS IN MYELODYSPLASTIC SYNDROME PATIENTS RECEIVING DECITABINE THERAPY
por: Zhang, Zheng, et al.
Publicado: (2023)

P721: VALIDATION OF THE MOLECULAR INTERNATIONAL PROGNOSTIC SCORING SYSTEM IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES DEFINED BY INTERNATIONAL CONSENSUS CLASSIFICATION
por: Hsuan Lee, Wan, et al.
Publicado: (2023)

P730: EVOLUTION OF IPSS-M RISK CATEGORIES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES FROM DIAGNOSIS TO HYPOMETHYLATING AGENT FAILURE
por: Chien, Kelly, et al.
Publicado: (2023)

P736: ANALYSIS OF RESPONSE RATES AND OUTCOMES IN ERYTHROID-PREDOMINANT MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH VENETOCLAX-BASED REGIMENS
por: Bazinet, Alexandre, et al.
Publicado: (2023)

P723: CLINICAL AND MOLECULAR ASSOCIATIONS WITH OUTCOMES IN HIGHER RISK MYELODYSPLASTIC SYNDROMES TREATED WITH HYPOMETHYLATING AGENTS PLUS VENETOCLAX
por: Bazinet, Alexandre, et al.
Publicado: (2023)

P695: SINGLE-CELL MULTIOMICS ANALYSIS OF MYELODYSPLASTIC SYNDROME PREDICTS CLINICAL RESPONSE TO TREATMENT WITH DNA DEMETHYLATION AGENT
por: Campillo-Marcos, Ignacio, et al.
Publicado: (2023)

1728. A Retrospective Analysis of 49 Cases of Histoplasmosis in Inflammatory Bowel Disease Patients on Tumor Necrosis Factor-α Antagonists
por: Harris, Courtney, et al.
Publicado: (2019)

P738: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THERAPY-RELATED MYELODYSPLASTIC SYNDROME: A RETROSPECTIVE COHORT MATCHED STUDY
por: Kotselyabina, Polina, et al.
Publicado: (2023)

P1318: THE IMPACT OF MELPHALAN DOSING IN COMBINATION WITH FLUDARABINE IN CLINICAL OUTCOMES OF PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES RECEIVING ALLO-HCT
por: Albanyan, O., et al.
Publicado: (2022)

A retrospective study of pyometra at five RSPCA hospitals in the UK: 1728 cases from 2006 to 2011
por: Gibson, A., et al.
Publicado: (2013)

Draft Genome Sequence of Escherichia coli E1728 Isolated from Marine Sediment in Hong Kong
por: Lai, Jennifer Y. H., et al.
Publicado: (2014)

1728P Evaluation of medical practices in oncology in a context of COVID-19 pandemic in France: Point of view of physicians, PRATICOVID study
por: Helissey, C., et al.
Publicado: (2020)

P790: THE EXPRESSION LEVEL OF WT1 MRNA IN PATIENTS WITH IDIOPATHIC CYTOPENIA OF UNDETERMINED SIGNIFICANCE (ICUS) PROGRESSING TO MYELODYSPLASTIC SYNDROME (MDS)
por: Ye, X., et al.
Publicado: (2022)

P712: SOLUBLE PD-L1 PREDICT POOR OVERALL SURVIVAL AND DISEASE PROGRESSION IN PATIENTS WITH DE NOVO MYELODYSPLASTIC SYNDROME
por: Yang, Xingcheng, et al.
Publicado: (2023)

P716: GENE EXPRESSION ANALYSIS REVEALS UNIQUE CHARACTERISTICS OF BONE MARROW MESENCHYMAL STROMAL CELLS IN MYELODYSPLASTIC SYNDROME WITH RING SIDEROBLASTS
por: Chen, Wanshu, et al.
Publicado: (2023)

P697: DISTINCT SPLICING ALTERATIONS ASSOCIATED WITH CLINICAL RESPONSE TO LUSPATERCEPT IN PATIENTS WITH LOWER‑RISK MYELODYSPLASTIC SYNDROMES FROM THE MEDALIST STUDY
por: Aluri, Srinivas, et al.
Publicado: (2023)

New targeted therapies in myelodysplastic syndrome: the role of farnesyltransferase and proteasome inhibitors
por: Gonçalves, A Cristina, et al.
Publicado: (2010)

Myelodysplastic syndrome in a patient with HCV cirrhosis. Case report
por: Olariu, Mihai, et al.
Publicado: (2013)

P745: MULTI-CENTER PHASE IB TRIAL OF THE HISTONE DEACTYLASE INHIBITOR ENTINOSTAT + PEMBROLIZUMAB IN MYELODYSPLASTIC SYNDROME OR ACUTE MYELOID LEUKEMIA REFRACTORY TO HYPOMETHYLATING AGENTS
por: Bewersdorf, Jan, et al.
Publicado: (2023)

P733: TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES RECEIVING LUSPATERCEPT IN ROUTINE CLINICAL PRACTICE IN THE UNITED STATES
por: Mukherjee, Sudipto, et al.
Publicado: (2023)

P699: MAGROLIMAB ALTERS THE TUMOR MICROENVIRONMENT TO IMPROVE BONE MARROW FUNCTIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS)
por: Johnson, Lisa, et al.
Publicado: (2023)

P715: TOX REGULATED CD8+ T LYMPHOCYTES EXHAUSTED IN MYELODYSPLASTIC SYNDROMES PATIENTS THROUGH ACTIVATING AKT/PI3K/MTOR PATHWAY
por: Niu, Haiyue, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_v22997cbatqvnn451qjtp7cn4i